Stem cell therapy for bone regeneration: fractures that won't heal, hip necrosis, and what the research shows
What the research shows about stem cells for bone — non-healing fractures and avascular necrosis of the hip — and what to ask before travelling to Mexico for it.
Short answer
Bone is one of the places where cell therapy has the longest research history. The best-studied uses are fractures that fail to heal (called nonunions) and early-stage avascular necrosis of the hip, where the bone loses its blood supply. In both, the published evidence is encouraging but still limited — and almost all of it comes from cells delivered directly into the bone during a surgical procedure, not from a stand-alone injection or IV drip. That detail matters more than any other when you compare what a clinic proposes with what the studies actually tested.
These therapies are considered investigational and are not approved by the U.S. FDA or Health Canada for bone conditions. Whether one is reasonable for your case is a decision for a licensed physician who has seen your imaging.
Where the research is strongest
| Condition | What was studied | What the evidence shows |
|---|---|---|
| Nonunion (a fracture that has not healed after months) | The patient’s own bone marrow, concentrated and injected into the fracture gap | Early studies report healing in many cases — and better results when more cells were delivered |
| Avascular necrosis of the hip, early stage | Core decompression surgery plus bone marrow concentrate placed into the femoral head | Meta-analyses suggest less pain, better function and fewer cases of collapse than surgery alone — with low-certainty evidence |
| Avascular necrosis, late stage (the femoral head has collapsed) | — | Cell therapy is not a substitute here; hip replacement remains the standard treatment |
| Osteoporosis | Mostly laboratory and animal research | Too early to present as a treatment for people |
| Jaw bone for dental implants | Cells combined with graft material | A dental-surgery field of its own, handled by oral surgeons |
Fractures that won’t heal
A 2005 study from a French university hospital injected concentrated bone marrow from the patient’s own hip into sixty tibial fractures that had stopped healing. Most of them healed. The fractures that did not heal had received noticeably fewer progenitor cells — an early sign that the dose of cells, not just the idea of using them, drives the result.
Avascular necrosis of the hip
Avascular necrosis (also called osteonecrosis) happens when part of the femoral head loses its blood supply and the bone starts to die. Caught early, surgeons often perform a core decompression: they drill a small channel into the femoral head to relieve pressure. Several recent meta-analyses compare that surgery alone with the same surgery plus bone marrow concentrate. They point in the same direction — better pain and function scores, and in some analyses fewer hips progressing to collapse or replacement.
The honest caveat comes from a 2026 systematic review written to inform the international ARCO clinical guideline for this disease: it rated the evidence that bone marrow concentrate reduces collapse as very low certainty, because most studies are small, short and observational. Promising, not settled.
The question that matters most: is this what was studied?
Most of the evidence above shares three features:
- The patient’s own bone marrow (autologous), usually concentrated the same day.
- Delivered into the bone itself, guided by imaging, often during surgery.
- Early disease — before the bone has collapsed or deformed.
Many protocols offered to international patients look different: donor cells (for example from umbilical cord tissue), expanded in a laboratory, and given by IV or a joint injection. That is not automatically wrong, and it may be the right call for some cases — but it is a different treatment from the one the bone studies describe, and you deserve to have that difference explained to you. A good physician will tell you plainly which evidence supports the protocol they recommend.
For how these cell sources differ, see our stem cell therapy overview.
Questions to ask before you travel
- What stage is my condition, according to the MRI or CT — and is it still early enough for a bone-preserving approach?
- Will the cells go into the bone, into the joint, or into the bloodstream? Why that route?
- Are the cells my own or from a donor, and which laboratory prepares them?
- Is surgery part of the plan, and who performs it?
- Is the clinic government-licensed (COFEPRIS), and is the laboratory licensed too? Our guide to choosing a clinic lists what to verify.
Common questions
Can stem cells regrow bone?
Mesenchymal stem cells can become bone-forming cells in the laboratory, and in the body they also release signals that support healing and blood-vessel growth. Researchers think much of the benefit in bone comes from those signals. What the current evidence does not support is the idea that an injection rebuilds a damaged bone on its own.
Can avascular necrosis of the hip be reversed?
In early stages, joint-preserving treatments aim to stop it progressing, and some patients avoid or delay a hip replacement. Once the femoral head has collapsed, the damage is structural and replacement is usually the recommended option. Your imaging decides which group you are in.
Is this the same as stem cell therapy for knee arthritis?
No. Arthritis treatment targets the joint lining and cartilage environment; bone treatments target the bone itself and usually involve a procedure. Our article on stem cell therapy for arthritis and joint pain covers the joint side.
Is it approved by the FDA?
No. Cell therapy for bone conditions is considered investigational and is not approved by the U.S. FDA or Health Canada for these uses. Read how Mexico regulates stem cell therapy for what that means in practice.
Further reading
- Percutaneous autologous bone-marrow grafting for nonunions — Hernigou et al., Journal of Bone and Joint Surgery, 2005
- Diagnosis and treatment of nontraumatic osteonecrosis of the femoral head: systematic review for the ARCO guideline — Parikh et al., Medical Sciences, 2026
- Core decompression combined with regenerative therapy in early femoral head necrosis: systematic review and meta-analysis — Tang et al., Frontiers in Pharmacology, 2025
- The advantages and shortcomings of stem cell therapy for enhanced bone healing — Chow et al., Stanford University, Tissue Engineering Part C, 2024
How Kern Stem Care helps
We send your imaging and history to government-licensed (COFEPRIS) physicians in our partner network, who tell you whether your case is a reasonable candidate and which approach the evidence supports. If it is, we coordinate the clinic, the laboratory, the travel and the follow-up — so you arrive knowing exactly what is planned and why.